Loading organizations...
The Trans Tasman Commercialisation Fund operates as an early-stage Australasian venture fund dedicated to transforming deep technology research from universities into viable commercial enterprises. It primarily invests in nascent ventures, providing critical seed capital to bridge the gap between academic innovation and market readiness. The fund's strategic approach involves identifying and nurturing high-potential university-derived technologies, facilitating their journey towards commercialisation.
The fund was established in April 2008 as a collaborative initiative. Key partners included Westscheme Superannuation, the South Australian and Victorian State governments, the New Zealand government, and five prominent universities: Monash University, Flinders University, University of South Australia, University of Adelaide, and University of Auckland. Grannus Securities was engaged to manage the fund from September 2009, overseeing its investment strategy and portfolio companies.
The fund’s beneficiaries are deep technology companies spun out of its partner universities, with investments spanning medical technology, surveillance systems, and sustainable energy solutions. It aims to propel groundbreaking academic research into the market, fostering innovation and creating new ventures across the trans-Tasman region. The long-term vision emphasizes accelerating the commercialisation pathway for university intellectual property.
Trans Tasman Commercialisation Fund has 1 tracked investment across 1 company. The latest tracked deal is $4.5M Series A Extension in Pathway Therapeutics in August 2010.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Aug 10, 2010 | Pathway Therapeutics | $4.5M Series A Extension | CM Capital, GBS Venture Partners | Breast Cancer Research Trust, NEW Zealand Growth Capital Partners |